Category: Medical Study

India: Peer-reviewed study of health care workers demonstrates that ivermectin can prevent Covid infection

Two doses (300 μg/kg/dose in a gap of 72 hours) of ivermectin chemoprophylaxis reduced COVID-19 infection by 83% among HCWs for one month. Ivermectin is a safe and effective strategy to prevent COVID-19, in the containment of pandemic alongside vaccine. Further research is required to guide the frequency of chemoprevention, acceptability, and cost-effectiveness in the community setting.

Read More »

The Meta-Analytical Fixers: An Ivermectin Tale – The Chloroquine Wars Part XL

The Roman/Hernandez meta-analysis comes at a politically contentious moment. Their language and behavior appear political. Their work is error-laden, takes research out of its true context, uses numbers that don’t seem to come from the actual studies, chooses papers testing ivermectin under the least favorable circumstances, gives unexplained and inappropriate weights to the small amount of data that stands as outliers to the bigger picture, and still drives a conclusion of “don’t use this” from a massive average mortality reduction that did not quite reach statistical significance. At the same time the authors consistently complain about the “low quality of evidence” represented by the studies they do and do not include, nearly all of which I would describe as produced by higher quality scientists who can at least tally numbers correctly.

Read More »

Hydroxychloroquine and its friends

Dr. Risch gives a succinct history of the politics of hydroxychloroquine and other useful existing medicines in the USA, which has had global effect, as many countries look to the USA for guidance. Corruption and manipulation from behind the scenes around the world are brought to the surface for scrutiny.

Read More »

Ivermectin for Prevention and Treatment of COVID-19 Infection

Moderate-certainty evidence finds that large reductions in COVID-19 deaths are possible using ivermectin. Using ivermectin early in the clinical course may reduce numbers progressing to severe disease. The apparent safety and low cost suggest that ivermectin is likely to have a significant impact on the SARS-CoV-2 pandemic globally.

Read More »

Journal Editors Resign Over Suppression of Ivermectin Research Paper – The Chloroquine Wars Part XXVII

In a letter dated the 23rd of April, 2021, four Guest Editors publicly resigned from the journal Frontiers in Pharmacology. Professor Maria Cristina Albertini, Professor Piero Sestili, Dr. Robert Malone, and Dr. Howard Haimes stepped down in protest over executive decisions not to publish two papers showing positive results of various agents in protecting against or treating COVID-19.

Read More »

How much proof do you want? Hundreds of studies conclude – treat Covid-19 early with hydroxychloroquine!

HCQ is effective for COVID-19. The probability that an ineffective treatment generated results as positive as the 235 studies to date is estimated to be 1 in 6 quadrillion (p = 0.00000000000000018).
Early treatment is most successful, with 100% of 29 studies reporting a positive effect (13 statistically significant in isolation) and an estimated reduction of 65% in the effect measured (death, hospitalization, etc.) using a random effects meta-analysis, RR 0.35 [0.25-0.50].
92% of Randomized Controlled Trials (RCTs) for early, PrEP, or PEP treatment report positive effects, the probability of this happening for an ineffective treatment is 0.0017.

Read More »

Hyperglycemia, hydroxychloroquine and the COVID‐19 pandemic

Hydroxychloroquine also can act as an oral hypoglycemic agent, as patients with diabetes taking hydroxychloroquine for rheumatologic diseases had a significant reduction in hemoglobin A1c when compared to methotrexate,40 and thus can serve to reduce hyperglycemia, a possible COVID‐19 risk factor for disease severity.

Read More »

Clinical outcomes of patients with mild COVID-19 following treatment with hydroxychloroquine in an outpatient setting

Our investigation of a large national cohort appears to support early administration (within the first 3 to 7 days of COVID-19 diagnosis) of HCQ in mild COVID-19 disease in an outpatient setting for reducing hospitalizations and deaths without any serious adverse HCQ-related effects.
If this finding is confirmed in future clinical trials, HCQ as a cheap and available drug may still play a role in a specific population with respect to reducing COVID-19 burden, particularly in resource-poor countries.

Read More »

A RANDOMIZED TRIAL – INTENSIVE TREATMENT BASED IN IVERMECTIN AND IOTA-CARRAGEENAN AS PRE-EXPOSURE PROPHYLAXIS FOR COVID- 19 IN HEALTHCARE AGENTS

The purpose of this study was to assess the effect of oral Ivermectin treatment, which has been associated with iota-carrageenan in repeated doses through the nasal and oral topical route, on the appearance and eventual progression of COVID-19 disease in a healthy population that are exposed to it and have a higher risk of contagion of SARS-COV-2 for being health personnel from

Read More »

The Chloroquine Wars Part VI – The Simple Logic of the Hydroxychloroquine Hypothesis

The Hydroxychloroquine Hypothesis: That there is some appropriate dosage of hydroxychloroquine, alone or in some combination with other medication, that successfully prevents some COVID-19 cases (PrEP/PEP) or treats some COVID-19 sufferers (Early/Late/Critical).
Remaining entirely unblemished after a year of trials and observations, the current evidence in favor of the Primary HCQ Hypothesis fully validates the HCQ Hypothesis. The logic is so simple that it almost feels like your livelihood would have to be on the line to deny it.

Read More »